drugset / Trial / NCT04667624

Study to Evaluate the Safety and PK of LODIENT Tablet 80/2.5mg in Healthy Adult Volunteers

NCT04667624

Phase 1 Completed 32 enrolled Hanlim Pharm. Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

A randomized, open label, single dose, 2-sequence, 4-period, cross-over phase I clinical trial to compare and evaluate the safety and pharmacokinetics after oral administration of "LodienT tablet 80/2.5mg(telmisartan/s-amlodipine)" and "TWINSTA tablet 80/5mg(telmisartan/amlodipine)" in healthy adult volunteers.

Timeline

Start
2020-02-29
Primary completion
2020-04-28
Completion
2020-05-18

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 5 mg Oral
Subject S-amlodipine Unknown 2.5 mg Oral
Comparator Telmisartan Other / unclassified 80 mg Oral

Indications